×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
How Much Of Magenta Therapeutics, Inc. (NASDAQ:MGTA) Do Institutions Own?
Yahoo News New Zealand
A look at the shareholders of Magenta Therapeutics, Inc. ( NASDAQ:MGTA ) can tell us which group is most powerful...
6 days ago
CEO of shuttered biotech Magenta Therapeutics makes leap to Flagship startup - Boston Business Journal
The Business Journals
The former CEO of a biotech that shut down after a patient death in a clinical trial has made his way to a new startup backed by Flagship...
8 months ago
Magenta Therapeutics: Potential Upside In The Merger, Wait To Buy More (MGTA)
Seeking Alpha
In May, the company announced its agreement to merge with private biotech company, Dianthus Therapeutics. The merger is expected to be completed...
9 months ago
3 Flagship biotechs make key exec hires—Chutes & Ladders
Fierce Biotech
Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or...
8 months ago
FMR LLC Acquires New Stake in Magenta Therapeutics Inc
Yahoo Finance
On September 29, 2023, FMR LLC (Trades, Portfolio), a prominent investment firm, made a significant move in the biotechnology sector by...
5 months ago
Dianthus Therapeutics Appoints Adam Veness, Esq., as General Counsel
PR Newswire
PRNewswire/ -- Dianthus Therapeutics, a clinical-stage biotechnology company dedicated to advancing the next generation of antibody...
10 months ago
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement
GlobeNewswire
(“Dianthus”), a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement...
12 months ago
Magenta Therapeutics, Dianthus agree to merge operations
Pharmaceutical Technology
Magenta Therapeutics has signed a definitive merger agreement to combine its business with clinical-stage biotechnology firm Dianthus.
12 months ago
Vividion Therapeutics Names Shawn Rose as Chief Development Officer
Business Wire
Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value,...
8 months ago
Magenta Therapeutics and Dianthus Therapeutics Merge
citybiz
The combined company will operate under the name, Dianthus Therapeutics, Inc., and its shares will begin trading on The Nasdaq Capital Market on...
7 months ago